Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The lymph node dissection in thyroid carcinoma].

Luca Cozzaglio1, Massimiliano Coladonato, Roberto Doci

  • 1Unità Operativa di Chirurgia Generale Oncologica, Istituto Clinico Humanitas, Rozzano, Milano. luca.cozzaglio@humanitas.it

Annali Italiani Di Chirurgia
|December 2, 2006
PubMed
Summary

Lymph node dissection (LD) in thyroid cancer is debated. For differentiated types, LD is only recommended for metastatic nodes, not for elevated thyroglobulin. Prophylactic LD is advised for medullary thyroid cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutritional status in retroperitoneal sarcoma: Implication of prognostic Nutritional Index (PNI) and skeletal muscle index (SMI) on postoperative and oncological outcomes.

Clinical nutrition ESPEN·2025
Same author

Evolution of Nutritional Status in Patients Undergoing Autologous and Allogeneic Hematopoietic Cell Transplantation or CAR-T Therapy: A Retrospective Observational Study.

Cancers·2025
Same author

Multiple melanomas in ichthyosis with confetti: One more piece of evidence.

The Australasian journal of dermatology·2023
Same author

If surgery has a future, it will be female.

Updates in surgery·2022
Same author

A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in <i>BRAF</i> V600E-Mutated Metastatic Melanoma.

Case reports in oncology·2022
Same author

Quality of life and patient satisfaction in outpatient thyroid surgery.

Updates in surgery·2021

Area of Science:

  • Oncology
  • Surgical Oncology

Context:

  • The role and indications for lymph node dissection (LD) in thyroid carcinoma remain debated due to histological variations and challenges in preoperative diagnosis of metastatic lymph nodes.
  • Prognostic factors associated with metastatic lymph nodes in thyroid cancer are not fully understood.

Purpose:

  • To analyze the indications and outcomes of lymph node dissection (LD) across different histological types of thyroid carcinoma and clinical scenarios.
  • To clarify the prognostic impact of lymph node metastases and the effectiveness of LD in various thyroid cancer subtypes.

Summary:

  • For differentiated thyroid carcinomas (papillary, follicular), metastatic lymph nodes (12-90%) do not appear to worsen prognosis. Level II-VI LD is indicated for confirmed metastases or recurrence, not for elevated thyroglobulin alone.
  • In medullary thyroid carcinoma (25-63% metastasis), Level II-VI LD is recommended for metastases, and prophylactic Level VI LD is always advised. Controversies exist regarding LD extent and indications based on calcitonin levels.

Related Experiment Videos

  • Anaplastic thyroid carcinoma, the most aggressive type, has a poor prognosis. LD is reserved for palliative care in cases of compression syndromes.

    • Impact:

    • Provides evidence-based guidance on lymph node dissection for differentiated and medullary thyroid cancers, aiding clinical decision-making.
    • Highlights areas of ongoing controversy, such as prophylactic dissection extent and the role of calcitonin in medullary thyroid cancer management.
    • Clarifies the limited role of LD in anaplastic thyroid carcinoma, focusing on palliative care.